Article Text
PDF
Abstract
Introduction/Background The rising incidence of endometrial cancer has stimulated researchers for a biomarker that is minimally invasive and has a potential for early detection and prognostication. The metabolomics is a novel, less visited field that has potential to identify new biomarkers for the early detection and prognostication of patients with endometrial cancers, given its strong association with unopposed estrogen exposure, obesity, and other characteristics of metabolic syndrome. Present study was conducted to assess the role of blood metabolites using targeted approach focussed on acylcarnitines, phosphatidylcholines and sphingolipids in the diagnostics and prognostics of endometrial cancer.
Methodology A pilot prospective case control observational study was conducted in the Department of Obstetrics and Gynaecology of a tertiary care teaching institute of India and metabolic signatures in 15 women diagnosed with endometrial cancer were studied. The samples were analysed using liquid chromatography-mass spectrometry (LC-MS).
Results The cases and controls were BMI matched (30.90± 5.53 vs 25.97± 3.48; P=.06). The FIA-based analysis of short-chain and long chain acylcarnitine revealed significant changes. The levels of C7:DC (pimeloylcarnitines) and C10:1 (Decenoylcarnitine) were higher in cases than controls. Long-chain acylcarnitines such as C12:1 (dodecenoylcarnitine), C14:1 (tetradecenoylcarnitine), and C14:2 (tetradecadienylcarnitine) were all significantly higher before treatment than post-treatment (p<0.05), whereas C18:2 (octadecadienylcarnitine) was significantly elevated in pre-and post-treatment cases compared with controls. In amino acid analysis, we found seven amino acids, viz., asparagine (Asn), histidine (His), lysine (Lys), methionine (Met), ornithine (Orn), phenylalanine (Phy), and threonine (Thy), were higher in controls than pre-treatment cases. Among 21 biogenic amines, creatinine was significantly lower in controls compared to pre-treatment cases, and levels of taurine (Tau) were significantly higher in controls than in pre-treatment cases.
Conclusion Oncometabolomics have a potential to identify unique metabolic signatures in patients with endometrial cancer. Our findings provide insight into the molecular pathology and changes related to intervention.
Targeted oncometabolites (Acylcarnitinene, aminoacids and phospholipids) in endometrial cancer ( pre-treatment and 8 wekks post-treatment) cases and BMI matched controls
Disclosures None